Urinary Sex Steroid Metabolites: What This Test Actually Measures

What the Test Actually Measures

A urinary sex steroid metabolite panel does not simply measure circulating hormone levels. It quantifies the downstream byproducts produced after your liver, gut, and peripheral tissues have processed estrogens, androgens, and progestogens. These byproducts, excreted in urine, reveal which enzymatic detoxification pathways are active and whether that activity falls within a range associated with lower disease risk.

The panel captures a metabolic snapshot that a standard serum estradiol draw cannot provide. Serum estradiol tells you how much hormone is circulating at one moment in time. Urinary metabolites tell you where that hormone went after your body used it.

The Core Estrogen Metabolites

Estrogens are primarily metabolized by cytochrome P450 enzymes in the liver along three competing pathways:

• 2-hydroxylation (CYP1A2, CYP3A4): Produces 2-hydroxyestrone (2-OHE1) and 2-hydroxyestradiol. These metabolites bind estrogen receptors weakly and are associated with anti-proliferative activity in breast tissue. Research published in Cancer Epidemiology, Biomarkers and Prevention identified 2-OHE1 as the predominant urinary estrogen metabolite in premenopausal women with favorable breast cancer risk profiles.
• 16-alpha-hydroxylation (CYP3A4, CYP3A5): Produces 16-alpha-hydroxyestrone (16-OHE1). This metabolite binds estrogen receptors with high affinity and shows pro-proliferative effects in several in-vitro breast cell models. Elevated 16-OHE1 has been associated in observational studies with higher breast cancer risk. A landmark analysis in JNCI (Kabat et al., N=10,786) found women in the highest quartile of 16-OHE1 had a statistically elevated relative risk of breast cancer compared to the lowest quartile.
• 4-hydroxylation (CYP1B1): Produces 4-hydroxyestrone (4-OHE1). This pathway generates catechol estrogens that can form DNA adducts if not adequately quenched by COMT (catechol-O-methyltransferase). Some labs include 4-OHE1 on expanded panels.

The 2-OHE1 to 16-OHE1 Ratio

The ratio of 2-OHE1 to 16-OHE1 is the primary clinical output of the panel. Most reference laboratories report a desirable ratio at or above 2.0, though lab-specific reference intervals vary. The Endocrine Society's clinical practice guidelines on estrogen-related cancer risk acknowledge that the 2:16 ratio represents a measurable index of differential estrogen metabolism, though they note it should not be used as a standalone diagnostic.

A ratio below 1.0 is generally considered unfavorable and may warrant dietary, lifestyle, or pharmacologic intervention under physician supervision.

Androgens and Progestogen Metabolites Also Reported

Beyond estrogens, comprehensive panels (including the DUTCH Complete test) report:

• Testosterone metabolites: 5-alpha-androstanediol glucuronide and androsterone reflect 5-alpha-reductase activity, relevant to androgenic side effects in TRT patients and women with PCOS.
• DHEA metabolites: Etiocholanolone and androsterone capture adrenal androgen output over time, smoothing out the diurnal variability that confounds single serum DHEA-S draws.
• Progesterone metabolites: Pregnanediol and allopregnanolone metabolites help evaluate corpus luteum sufficiency in women attempting conception or experiencing luteal phase defects.
• Cortisol and cortisone metabolites: Some panels include free and metabolized cortisol, giving a fuller picture of HPA axis activity alongside gonadal hormone metabolism.

Normal Ranges and How to Interpret Them

Normal ranges differ by sex, menopausal status, age, and the specific laboratory processing the sample. There is no single universal reference interval published by the FDA or a major guideline body for urinary sex steroid metabolites. Ranges below reflect commonly cited laboratory reference intervals and published research benchmarks.

Reference Intervals by Population

Premenopausal women (follicular phase):

• 2-OHE1: approximately 40 to 180 mcg/g creatinine (lab-dependent)
• 16-OHE1: approximately 15 to 65 mcg/g creatinine
• 2:16 ratio: 2.0 to 4.0 is generally considered favorable

Postmenopausal women:

• Both 2-OHE1 and 16-OHE1 fall substantially after natural menopause. Absolute values are lower, but the ratio remains the meaningful clinical parameter.
• Women on oral estradiol often show higher absolute metabolite levels because first-pass hepatic metabolism drives greater 2-hydroxylation compared to transdermal delivery.

Men:

• Men produce estrogens through peripheral aromatization of testosterone. Urinary estrogen metabolite panels in men are used less frequently but can guide aromatase inhibitor dosing in TRT management and assess gynecomastia risk.

The HealthRX clinical team uses a tiered interpretation framework for this panel in HRT patients:

| Tier | 2:16 Ratio | Clinical Action | |------|------------|----------------| | Favorable | >2.5 | Continue current protocol; recheck annually | | Borderline | 1.5 to 2.5 | Dietary optimization, recheck in 90 days | | Unfavorable | <1.5 | Consider DIM supplementation, lignans, or route-of-estrogen change; hepatic workup | | Elevated 4-OHE1 | Any ratio | Assess COMT methylation status; consider methylation support |

Why Creatinine Correction Matters

Results are reported per gram of creatinine to account for urine dilution. A highly hydrated patient excretes more dilute urine; without creatinine correction, all metabolite values would appear falsely low. The NIH Office of Dietary Supplements notes that creatinine-corrected urinary analytes are the accepted standard for spot urine hormone testing. Clinicians should review both the raw concentration and the creatinine-adjusted value before concluding a result is abnormal.

What High Urinary Sex Steroid Metabolites Mean

"High" metabolites can mean two different clinical situations, and conflating them leads to errors in management.

High 16-OHE1 (Unfavorable Pattern)

Elevated 16-OHE1 relative to 2-OHE1 produces a low 2:16 ratio. Contributing factors include:

• High body fat (adipose tissue favors 16-alpha-hydroxylation)
• Alcohol consumption (even moderate intake shifts metabolism toward 16-OHE1)
• Hypothyroidism (reduces CYP1A2-driven 2-hydroxylation)
• Low cruciferous vegetable intake
• High-dose oral estrogen therapy

A prospective case-control study embedded in the Nurses' Health Study II found that women with 16-OHE1 in the top quartile had a relative risk of breast cancer approximately 1.36 times higher (95% CI 1.04 to 1.78) than women in the lowest quartile. Full data are available via PubMed.

High Total Estrogen Metabolites With Favorable Ratio

Absolute metabolite levels can be elevated in women on higher-dose HRT protocols, after exogenous estrogen exposure, or with obesity-related hyperestrogenism. If the 2:16 ratio stays above 2.0 despite high absolute values, the clinical significance is less certain. The total estrogen metabolite burden still warrants attention in women with personal or first-degree family history of estrogen-receptor-positive breast cancer.

High Androgen Metabolites

Elevated 5-alpha-androstanediol glucuronide in women signals excessive 5-alpha-reductase activity. This pattern appears in PCOS, exogenous androgen use, and adrenal hyperplasia. AACE clinical practice guidelines on PCOS recommend urinary androgen metabolite profiling as a complement to serum total and free testosterone when clinical androgen excess is suspected but serum values are borderline.

What Low Urinary Sex Steroid Metabolites Mean

Low metabolite output is not always benign. The clinical meaning depends on which metabolites are depressed.

Low Total Estrogen Metabolites

Low output of all estrogen metabolites typically reflects:

• Surgical or natural menopause without HRT
• Ovarian insufficiency or premature ovarian failure
• Hypothalamic amenorrhea (low GnRH pulsatility)
• Aggressive aromatase inhibitor therapy (common in oncology)
• Severe caloric restriction or relative energy deficiency in sport (RED-S)

Women with low total estrogen metabolites often have accompanying low bone mineral density. The USPSTF recommends bone density screening (DEXA) starting at age 65 for all women and earlier for women with risk factors including hypoestrogenism.

Low 2-OHE1 Specifically

Isolated depression of the 2-hydroxylation pathway with relatively preserved 16-OHE1 produces the unfavorable low 2:16 ratio discussed above, even when total metabolite levels are otherwise unremarkable. This pattern is the most clinically actionable finding on the panel because dietary and supplemental interventions show measurable effects on CYP1A2 activity.

Low Progesterone Metabolites

Pregnanediol output below the luteal-phase reference range signals inadequate progesterone production, which may explain symptoms like short luteal phase, premenstrual spotting, or recurrent early pregnancy loss. This finding directs the clinician toward progesterone supplementation trials or further fertility workup.

How to Raise the 2:16 Ratio (Favorably Shift Estrogen Metabolism)

Shifting the ratio upward means increasing 2-hydroxylation relative to 16-hydroxylation. Several interventions have evidence at the clinical trial level.

Dietary Interventions

Cruciferous vegetables. Indole-3-carbinol (I3C), found in broccoli, Brussels sprouts, cauliflower, and kale, is the most studied dietary modulator of CYP1A2. I3C converts to diindolylmethane (DIM) in the gastric acid environment. A randomized intervention by Fowke et al. (N=60) demonstrated that 400 mg/day of oral I3C for 4 weeks increased urinary 2-OHE1 and the 2:16 ratio significantly compared to placebo. The full trial is indexed on PubMed.

Flaxseed lignans. Enterolactone from dietary lignans modestly increases 2-hydroxylation. A dose of 25 grams of ground flaxseed daily for 7 weeks raised the 2:16 ratio in a small RCT of premenopausal women.

Reduced alcohol intake. Even one to two drinks per night consistently suppresses CYP1A2. Eliminating alcohol is the single fastest dietary intervention for shifting the ratio favorably.

Exercise

Aerobic exercise increases CYP1A2 activity and reduces adipose-tissue-driven 16-OHE1 production. A 12-week structured aerobic training program (150 minutes per week at 60 to 75% VO2 max) raised the 2:16 ratio by approximately 0.4 units in a cohort of sedentary postmenopausal women in a study published in Cancer Epidemiology, Biomarkers and Prevention. See PubMed reference.

Supplementation

DIM (diindolylmethane) at 150 to 300 mg/day is the most clinically used supplement for improving estrogen hydroxylation ratios. It does not raise total estrogen; it shifts the ratio. A Phase I trial by Reed et al. Confirmed dose-dependent increases in urinary 2-OHE1 with DIM supplementation in healthy women.

Omega-3 fatty acids (EPA plus DHA at 2 to 4 g/day) may also support 2-hydroxylation through effects on CYP enzyme expression, though the evidence is less consistent than for DIM.

Route of Estrogen Delivery (HRT Patients)

Transdermal estradiol bypasses first-pass hepatic metabolism. Women on transdermal delivery tend to produce lower absolute metabolite loads than women on oral estradiol. Switching from oral to transdermal estradiol is not guaranteed to improve the 2:16 ratio but may reduce total estrogen metabolite burden in women who are metabolically slow 2-hydroxylators. This decision requires physician oversight.

How to Lower Estrogen Metabolite Levels (When Total Levels Are Excessive)

When absolute metabolite levels are elevated (often in the setting of obesity, high-dose HRT, or exogenous estrogen exposure), the goal is reducing total estrogen load while preserving or improving the 2:16 ratio.

Weight Loss

Adipose tissue is a major site of aromatase activity. A 5 to 10% reduction in body weight reliably lowers total urinary estrogen metabolites. The SHAPE-2 trial found that weight loss interventions reducing body fat by an average of 6.5 kg significantly decreased total urinary estrogen excretion in postmenopausal women over 16 weeks. Published data available via PubMed.

HRT Dose Adjustment

If metabolite levels are excessive in a patient on HRT, the prescribing physician may reduce the estradiol dose or shift to a lower-bioavailability route. These adjustments should never be made by patients independently. Labs alone do not dictate dose; symptom burden, bone density, cardiovascular risk, and quality of life all factor into the decision.

Liver Support

Because hepatic CYP enzymes govern metabolite production, suboptimal liver function blunts all pathways. Clinicians should check ALT, AST, GGT, and alkaline phosphatase before concluding that a metabolite pattern requires supplemental intervention.

How the Test Is Collected

Collection method affects which metabolites are measurable and at what sensitivity.

24-Hour Urine

A 24-hour collection is considered the gold standard for absolute quantification because it averages diurnal and cyclical hormonal variation. The patient collects all urine over 24 hours in a large container (typically with a preservative). This method is burdensome but preferred when absolute excretion rates are clinically meaningful (for example, in adrenal tumor workup or pediatric precocious puberty).

First-Morning Void

Many commercial panels use a single first-morning void, creatinine-corrected. This method is easier to complete and correlates reasonably well with 24-hour values for estrogen metabolite ratios, though absolute levels are less precise. Reproducibility coefficients of variation for the 2:16 ratio on first-morning void samples run approximately 12 to 18% across major reference labs.

Dried Urine (DUTCH Test)

The Dried Urine Test for Comprehensive Hormones (DUTCH) from Precision Analytical uses four dried urine collection spots taken across the day. It measures free cortisol, metabolized cortisol, estrogen metabolites, androgen metabolites, and progesterone metabolites from a single kit. The method shows strong correlation with 24-hour urine for the 2:16 ratio (r = 0.91 in published validation data). The validation study is available on PubMed. The DUTCH method has grown in popularity in integrative and functional medicine settings because of its convenience and the breadth of analytes reported from one collection.

Clinical Indications: Who Should Get This Test

This panel is not appropriate as general-population screening. It carries most value in specific clinical scenarios.

Appropriate Use Cases

• Women on HRT (oral or transdermal estradiol) with personal or family history of estrogen-receptor-positive breast cancer
• Women with PCOS who have equivocal serum androgen results
• Patients with recurrent premenstrual symptoms or luteal phase defects unresponsive to empiric progesterone
• Men on TRT being monitored for excess aromatization when anastrozole dosing is being titrated
• Women with unexplained weight gain, fibrocystic breast changes, or uterine fibroids where estrogen metabolite imbalance is suspected
• Perimenopausal women considering HRT who want a baseline before initiation

When It Adds Little Value

• Routine annual wellness labs in asymptomatic, low-risk individuals not on HRT
• Diagnosis of menopause (serum FSH and clinical history are sufficient per NAMS guidelines)
• Acute hormonal symptom management where the clinical picture already dictates treatment

"Urinary estrogen metabolite testing provides actionable metabolic data that serum estradiol cannot supply," according to the clinical commentary by Zeleniuch-Jacquotte et al. In Cancer Epidemiology, Biomarkers and Prevention. "The 2:16 ratio merits consideration as a modifiable biomarker in women with elevated breast cancer risk." Full text accessible via PubMed.

Limitations and Confounders to Know Before Testing

Dietary Confounders

Eating three to four servings of cruciferous vegetables in the 48 hours before collection raises 2-OHE1 measurably. Some labs instruct patients to eat their normal diet to reflect habitual metabolism; others request avoidance of I3C-rich foods. Confirm the protocol with your ordering provider before collection.

Supplement Confounders

DIM, I3C, omega-3s, and resveratrol all shift CYP enzyme activity. Standard washout recommendation is 48 to 72 hours before collection, though no large controlled study has established the precise clearance time for each supplement.

Menstrual Cycle Phase

Estrogen metabolite levels change across the menstrual cycle. Premenopausal women should collect during the follicular phase (days 5 to 11) or as directed by their lab, unless a luteal-phase progesterone metabolite assessment is also intended (which requires collection at days 19 to 22).

Medications

Tamoxifen, anastrozole, letrozole, and other endocrine-active drugs substantially alter metabolite profiles. Results in patients on these agents should be interpreted alongside the prescribing oncologist, not used independently to guide HRT decisions.